SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 21st, 2023 • Akari Therapeutics PLC • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 20, 2023, between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Pre-Funded Warrant to purchase ordinary shares represented by american depositary shares AKARI THERAPEUTICS, PLCAkari Therapeutics PLC • September 21st, 2023 • Pharmaceutical preparations
THIS Pre-Funded WARRANT to purchase ordinary shares represented by American depositary shares (the “Warrant”) certifies that, for value received, [●] or [its] assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Company”), up to [●] ordinary shares, par value $0.0001 per share, of the Company (the “Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”) represented by [●] American Depository Shares (“ADSs”, each ADS representing 2,000 Ordinary Shares, and the ADSs issuable hereunder, the “Warrant ADSs”). The purchase price of one Warrant ADS under this Warrant shall be equal to the Exercise Price, as
